Cabaletta Bio outlines 2026 strategic priorities for autoimmune therapy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech stocks weigh on Wall Street as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- U.S. EV market shows signs of bottoming out: Bernstein
Cabaletta Bio Announces 2026 Strategic Priorities
January 12, 2026 8:00 AM ESTRegistrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission including an outpatient dosing option using a single weight-based doseÂ
IND amendment cleared to manufacture rese-cel with the automated, scalable Cellares platform based on multiple successful engineering runs; clinical manufacturing data expected in 1H26 to confirm GMP readiness, including supply chain logistics
New durability data without preconditioning and higher dose initial clinical data from RESET-PV expected in 1H26; dose-ranging data from RESET-SLE without preconditioning anticipated in 2026
Complete Phase 1/2 data anticipated in... More
